Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ImmunityBio, Inc. Director's Dealing 2016

May 28, 2016

31529_dirs_2016-05-27_11537b45-001c-4412-8b5a-9dce89c2aa78.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NantKwest, Inc. (NK)
CIK: 0001326110
Period of Report: 2016-05-26

Reporting Person: Thomas John C (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-05-26 Common Stock M 277725 $0.2161 Acquired 335789 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-05-26 Stock Option (right to buy) $0.2161 M 277725 Disposed 2024-03-17 Common Stock (277725) Direct

Footnotes

F1: Subject to the reporting person's continuing service, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month on the same day as the vesting commencement date, such that the shares subject to the option shall become fully vested and exercisable on the second (2nd) anniversary of the vesting commencement date. The vesting commencement date for this option is March 17, 2014. The option originally covered 200,000 pre 1.8515 for 1 forward split shares.